Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$24.50 USD

24.50
647,256

+0.24 (0.99%)

Updated Apr 24, 2024 02:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

On Incyte's (INCY) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition recently.

Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Alkermes (ALKS) settling at $26.70, representing a -1.26% change from its previous close.

Alkermes (ALKS) Stock Dips While Market Gains: Key Facts

The latest trading day saw Alkermes (ALKS) settling at $26.94, representing a -0.41% change from its previous close.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Why Alkermes (ALKS) Could Beat Earnings Estimates Again

Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Alkermes (ALKS) Registers a Bigger Fall Than the Market: Important Facts to Note

Alkermes (ALKS) closed the most recent trading day at $27.74, moving -1% from the previous trading session.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know

In the most recent trading session, Alkermes (ALKS) closed at $28.20, indicating a +0.93% shift from the previous trading day.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Alkermes (ALKS) Outperforms Broader Market: What You Need to Know

Alkermes (ALKS) reachead $27.92 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.

Why Is Alkermes (ALKS) Down 1.3% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition

Alkermes' (ALKS) growth is being driven by the sale of its proprietary products, Vivitrol, Aristada and Lybalvi. However, stiff competition in the target market remains an overhang.

Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View

Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales. Stock price drops 5% post the announcement.

CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected

CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.

Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss

Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.

Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss

Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.

Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat

Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. Shares fall.

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) Dips More Than Broader Market: What You Should Know

Alkermes (ALKS) concluded the recent trading session at $27.18, signifying a -1.74% move from its prior day's close.

Alkermes (ALKS) Stock Moves -0.84%: What You Should Know

Alkermes (ALKS) closed the most recent trading day at $29.60, moving -0.84% from the previous trading session.

Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know

Alkermes (ALKS) closed the most recent trading day at $28.85, moving -1.16% from the previous trading session.

Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.